Stay updated on Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page's revision label changed from v3.5.3 to v3.5.4. This reflects a minor update to the page version metadata and does not alter core study content.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page revision was updated from v3.5.2 to v3.5.3, representing a small, non-substantive update to the page. The core study details and data are not indicated to have changed.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page now displays Revision: v3.5.2, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision: v3.5.0 has been added and revision v3.4.3 has been removed.SummaryDifference0.1%

- Check82 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check110 days agoChange DetectedRevision: v3.4.2 was added and the prior funding notice (v3.4.1) was removed; there are no changes to study content, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.